Context Therapeutics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $28.7M
- Price
- $0.3126
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.86%
- Volume
- 464.2K
About
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Quick stats
Shares outstanding91.9M
Computed float90.6M
Float / shares98.6%
Cash runway (months)14.2
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001842952
AI Summary
AI-generated1/9
minorbullishclinical trial
Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
Context Therapeutics dosed the first patient in the Phase 1 trial of CT-202, a Nectin-4 x CD3 T cell engaging bispecific antibody being developed for solid tumors.
The open-label, dose-escalation study (NCT07545122) is evaluating CT-202 as a monotherapy in patients with Nectin-4-expressing recurrent, unresectable or metastatic refractory/resistant urothelial, colorectal and triple-negative breast cancers.
Management expects initial Phase 1a data in the second half of 2027, making this an early pipeline-validation step rather than a near-term catalyst for the clinical-stage biotech.
Red flags
- pre-revenue clinical-stage biotech; forward-looking statements cite financing availability and sufficiency-of-funding risk
- risk factors reference discontinuation of internal development of CT-95 under portfolio prioritization
- initial Phase 1a data not expected until H2 2027 -- long data timeline with enrollment risk